Across TCGA pan-cancer cohorts, FOXD4L5 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of FOXD4L5’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where FOXD4L5 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types FOXD4L5 is over-expressed in tumor, although a few such as BRCA and KICH show the opposite, repressed pattern.

PAAD, BRCA, and STAD are the cancer types where FOXD4L5 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FOXD4L5 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PAAD	Female	All	+0.095	.002	2	view →
BRCA	All	III,IV	−0.027	.023	2	view →
STAD	Male	II,III,IV	+0.024	.014	2	view →
KICH	All	All	−0.014	.015	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: FOXD4L5 RNA expression & survival · all FOXD4L5 data types